Beckman Coulter Diagnostics DxN VERIS Molecular Diagnostics System: Proven to be Easy to Learn and Operate

Beckman Coulter recently commissioned independent system performance trials of the new DxN VERIS Molecular Diagnostics System and results show that the system is easy to operate with technicians fully operational on the system following just 20 minutes training.

Following a trial undertaken at Sheffield Teaching Hospital NHS Trust, UK, Duncan Whittaker, Laboratory Manager Virology, stated “Training staff to use the DxN VERIS is very quick and straightforward, taking just 20 minutes. Furthermore, as there is less hands-on intervention required, the laboratory could achieve more without any increase in staff. With an annual cost improvement package to meet, anything that helps to increase productivity is a bonus.”

“In terms of addressing increasing workloads, the reduced manual intervention required for DxN VERIS allows more work to be performed per member of staff. The more efficient workflow would free staff to perform other tasks, which would allow the laboratory to develop new services and further increase the department’s test repertoire. This, and improved turnaround times, would help our laboratory to remain competitive in an increasingly competitive environment.”

“The ease of use of the DxN VERIS would help to address staffing issues, as routine operation could be performed by medical laboratory assistants, allowing biomedical scientists to be redeployed more effectively in more skilled areas”, Whittaker concluded.

The DxN VERIS Molecular Diagnostics System consolidates DNA extraction, amplification and detection within a single automated instrument. By reducing manual intervention, and automating the steps from sample loading to reporting of results, this system has the potential to revolutionise laboratory workflows and reduce time to results. There is no lengthy set-up – all consumables/reagents are refrigerated on-board: HBV, HCV, HIV-1 and CMV viral load assays are currently available; these will be followed by assays for STDs/women’s health and Hospital Acquired Infections.

For further information about the DxN VERIS Molecular Diagnostics System and a copy of the full Sheffield case study that was published in Pathology in Practice, Volume 16, Issue 3, August 2015, please contact: Tiffany Page, Senior Pan European Marketing Manager Molecular Diagnostics, Email: info@beckmanmolecular.com or visit www.beckmancoulter.com/moleculardiagnostics.

About Beckman Coulter

Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimise the clinical laboratory. Beckman Coulter’s instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes—offering a broad portfolio of chemistry, immunoassay, haematology, urinalysis, microbiology, automation, information systems and molecular diagnostics. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com.

About the DxN VERIS Molecular Diagnostics System and Assays

The DxN VERIS Molecular Diagnostics System is a fully automated sample‐to‐answer instrument for the quantitative analysis of molecular targets. It integrates sample introduction, nucleic acid extraction, reaction setup, real‐time PCR amplification and detection (using TaqMan chemistry), and results interpretation for a fully streamlined workflow. A sample tube is simply loaded onto the DxN VERIS Molecular Diagnostics System and all steps after that are performed automatically, giving molecular diagnostics laboratories the freedom and control to provide the right answers at the right time.

The growing menu of assays for use on the DxN VERIS Molecular Diagnostics System includes the CE-marked DxN VERIS CMV Assay (for the quantitative determination of human Cytomegalovirus (CMV) in plasma), DxN VERIS HBV Assay (for quantitative measurement of Hepatitis B Virus (HBV) in human plasma and serum) and DxN VERIS HCV Assay (for quantitative measurement of Hepatitis C Virus (HCV) in human plasma and DxN VERIS HIV-1 Assay (for quantitative detection of Human Immunodeficiency Virus type 1 (HIV-1) in plasma).

Beckman Coulter is committed to ongoing growth and aims to rapidly expand the DxN VERIS Molecular Diagnostics System menu and has many other assays in development.